Clinical Trial Update: Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial [Phase 3]

View source ↗

Summary

Open-label extension phase 3 trial of arimoclomol in sporadic inclusion body myositis has terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inclusion Body Myositis

Drugs mentioned

• Arimoclomol (arimoclomol)

Snippet

Sponsor: ZevraDenmark | Conditions: Inclusion Body Myositis | Phase 3 | Status: TERMINATED | Results posted: 2023-09-15